Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ovarian Cancer | Ovaries